Hippocampal Volume in First-Episode Psychoses and Chronic Schizophrenia

A High-Resolution Magnetic Resonance Imaging Study

Dennis Velakoulis, FRANZCP; Christos Pantelis, MRCPsych; Patrick D. McGorry, FRANZCP, PhD; Paul Dudgeon, BSc; Warrich Brewer, BPsych; Mark Cook, FRACP; Patricia Desmond, FRACR; Nicola Bridle, BSc; Paul Tierney, BSc; Vanessa Murrie, BSc; Bruce Singh, FRANZCP, PhD; David Copolov, FRANZCP, PhD

Background: It has been proposed that the hippocampus is a potential site for a neurodevelopmental lesion in schizophrenia. While smaller hippocampal volumes have been described in chronic schizophrenia, there have been few magnetic resonance imaging studies in first-episode psychosis. Furthermore, no studies have examined the specificity of this finding to first-episode schizophrenia, compared with first-episode affective psychosis.

Methods: Hippocampal and whole-brain volumes were estimated using high-resolution magnetic resonance imaging in 140 controls, 46 patients with chronic schizophrenia, and 32 patients with first-episode psychosis.

Results: Patients with chronic schizophrenia and first-episode psychosis had significantly smaller hippocampal volumes as compared with controls. Within the first-episode group, both patients with schizophrenia/schizophreniform psychosis and those with affective psychosis had smaller left hippocampal volumes as compared with controls. Smaller right hippocampal volumes were associated with age and illness duration in patients with chronic schizophrenia. Hippocampal volumes were not correlated with age of illness onset or medication dosage in either patient group.

Conclusions: These data show that smaller hippocampal volumes are present from the onset of illness. While these findings would support the neurodevelopmental model of schizophrenia, the finding of smaller left hippocampal volume in patients with first-episode schizophrenia and affective psychosis does not support the prediction that smaller hippocampi are specific to schizophrenia. The association of smaller right hippocampal volumes with increased illness duration in chronic schizophrenia suggests either that there is further neurodegeneration after illness onset or that bilateral small hippocampi predict chronicity.
SUBJECTS AND METHODS

SUBJECTS

Consecutive first-episode inpatients were recruited from the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. Study inclusion criteria were (1) age at onset between 16 and 30 years; and (2) currently psychotic as reflected by the presence of at least 1 symptom (either delusions, hallucinations, disorder of thinking and/or speech other than simple acceleration or retardation, and disorganized, bizarre, or markedly inappropriate behavior). DSM-III-R diagnoses43 were based on medical record review and the Royal Park Multidagnostic Instrument for Psychosis,44 which was administered within 2 weeks of admission. There was no difference in the age ($t_{105}=0.30, P = .62$) or sex ($X^2 = 0.31, P = .58$) of the study group compared with all first-episode Early Psychosis Prevention and Intervention Centre inpatients for the period 1995 to 1996. Patients with chronic schizophrenia were recruited from the Rehabilitation Unit, Royal Park Hospital, Melbourne. Diagnoses were based on clinical symptoms and medical record review using DSM-III-R criteria.44 All patients with chronic schizophrenia had at least 2 years of neuroleptic exposure at the time of scanning. Healthy volunteers were recruited by approaching ancillary hospital staff and through advertisement. These subjects were recruited from similar sociodemographic areas as the patients.

All subjects were screened for comorbid medical and psychiatric conditions by clinical assessment and physical and neurologic examination. Exclusion criteria were a history of significant head injury, seizures, neurologic diseases, impaired thyroid function, steroid use, or DSM-III-R criteria of alcohol or substance abuse or dependence. Control subjects with a personal or family history of psychiatric illness were excluded.

Two hundred twenty-nine subjects were recruited for the study but only 218 were included in the analysis (Table 1). Following scanning, 11 subjects were excluded; 6 patients with chronic schizophrenia (temporal lobe lesion, 2 patients; basal ganglia infarction, 1 patient; frontal lobe contusion, 1 patient; diagnosis revised to schizoaffective disorder, 2 patients); 4 first-episode patients (patient subsequently deemed not first-episode, 3 patients; steroid use prior to scanning, 1 patient); and 1 control subject (occipital lobe cyst).

Clinical information, including handedness,46 premorbid IQ as assessed by the New Adult Reading Test,47 and medication data (expressed in the relevant milligram equivalents48), was obtained from patient interview and medical record review (Table 1). The National Adult Reading Test has been shown to be stable over time in patients with schizophrenia49 and provides a better estimate of the highest premorbid level of functioning than the Wechsler Adult Intelligence Scale–Revised,50 which may yield reduced scores in patients with schizophrenia following the onset of illness.51 First-episode patients were neuroleptic-naive prior to admission but had received antipsychotic medication for a mean of 30.8 days (SD = 23.4 days; range, 1-149 days) prior to scanning. Medication doses for patients with chronic schizophrenia were calculated for the 30 days prior to scanning. Thirteen patients with chronic schizophrenia had incomplete medication data. Written informed consent was obtained from all subjects. The study was approved by local research and ethics committees.

MRI PROTOCOL AND DATA ANALYSIS

All patients and 46 controls underwent scanning with a 1.5-Tesla scanner (Signa Horizon; General Electric Medical Systems, Milwaukee, Wis) at the Royal Melbourne Hospital. The remaining 97 control subjects were scanned at an identical scanner at Cabrini Hospital, Melbourne. Head movement was minimized by foam padding and straps across the forehead and chin. Patients received their normal medication on the day of scanning.

A 3-dimensional volumetric spoiled gradient recalled echo in the steady state sequence generated 124 contiguous, 1.5-mm coronal slices. Imaging parameters in the Cabrini and Royal Melbourne Hospitals were time-to-echo, 9 and 3.3 milliseconds; time-to-repetition, 36 and 14.3 milliseconds; flip angle, 35° and 30°; matrix size, 256 × 192 and 256 × 256; field of view, 20 × 15 cm and 24 × 24 cm matrix; voxel dimensions, 0.781 × 0.781 × 1.5 mm and 0.937 × 0.937 × 1.5 mm, respectively. Each scanner was calibrated fortnightly using the same proprietary phantom to ensure stability and accuracy of measurements. There were no significant differences in structural measures between scanners for control subjects (for whole-brain volumes, $t_{138} = 0.55, P = .58$; for total hippocampal volume, $t_{135} = 0.82, P = .41$; for total hippocampal volume, $t_{135} = 0.55, P = .58$). All subjects in analyses 2 and 3 below underwent scanning at the Royal Melbourne Hospital.

Comparison of the 3 groups in analysis 1 revealed that there were no differences in height or handedness, although there were more female control subjects ($X^2 = 14.6, P < .001$) and the first-episode subjects were younger ($t_{215} = 2.43, P = .02$). In analysis 2 there were no sex, height, or handedness differences between the groups. Patients with chronic schizophrenia were older than first-episode patients ($t_{135} = 7.49, P < .001$) and controls ($t_{135} = 7.82, P < .001$). The control subjects had higher premorbid IQs than both chronic ($t_{135} = 2.25, P < .05$) and first-episode patients ($t_{135} = 3.81, P < .001$). The first-episode subgroups and controls (analysis 3) did not differ in sex, age, handedness, or height, although first-
Magnetic resonance imaging data were transferred from digital tape to an IBM 6000 RISC workstation (IBM North America, New York, NY) and analysed using ANALYZE 7.2 software (Mayo Clinic, Rochester, Minn). A code was used to ensure patient confidentiality and blind rating of data. A neuroradiologist reviewed all MRI films.

Hippocampal volumes were estimated using a manual tracing technique and defined anatomical criteria.21 Hippocampal boundaries were defined as posterior (slice with greatest length of continuous fornix); medial (open end of the hippocampal fissure posteriorly, uncus in the hippocampal body and medial aspect of ambient gyrus anteriorly); lateral (temporal horn of lateral ventricle); anterior (white matter inferior to the hippocampus); superior (superior border of hippocampus); and inferior (alveus was used to differentiate hippocampal head from amygdala). The anterior border was the most difficult to identify consistently and was aided by moving between slices before and after the index slice. Hippocampal length was estimated as the number of slices per hippocampus. One rater (D.V.) performed all hippocampal tracings included in the analyses. The intraclass correlation for interrater reliability (D.V.) was 0.85 and for interrater reliability (D.V. and M.C.) was 0.72 in 10 subjects.

Whole-brain volumes were estimated, with investigators blind to diagnosis, using a 3-dimensional morphometric procedure that included the cerebellum, brainstem, and ventricles but not cisterns or sulcal cerebrospinal fluid. A thresholding technique maximally separated brain and skull to produce minimum and maximum pixel values. These values were applied to all slices in a series of erosions and dilatations, the number of which was determined by the rater. Images were divided among 3 raters (D.V., N.B., P.T.) for whom interrater reliability on 10 randomly selected images was 0.85 and for interrater reliability (D.V. and M.C.) was 0.98.

STATISTICAL ANALYSIS

Three analyses were carried out on whole-brain and hippocampal volumes. The first included 140 controls and all patients (Table 2). Differences in whole-brain volume were assessed by a 1-way analysis of variance (ANOVA) defined by a 3-level (control, chronic, and first-episode) between-subjects group factor. Differences in hippocampal volume were assessed by a repeated-measures ANOVA with the same between-subjects group factor and a 2-level (right and left hippocampal volumes) within-subjects laterality factor.

The second set of analyses used corresponding 1-way and 2-way analysis of covariance designs to control for the possible confounding effects of concomitant variables. For whole-brain volume, the covariates were age, sex, height, and premorbid IQ. For hippocampal volume, the same 4 covariates were used, plus whole-brain volume (Table 3).

Premorbid IQ scores were available on 42 controls, 34 chronic, and all 32 first-episode psychosis cases. The control subgroup did not differ from the remaining 98 control cases in whole-brain volume (t138 = 1.67, P = .98) or left (t138 = −0.10, P = .92) and right (t138 = −0.32, P = .75) hippocampal volumes.

The third set of analyses examined the diagnostic specificity of structural differences by subdividing the first-episode patients into a subgroup of 16 with schizophrenia/schizoaffective psychosis, and a subgroup of 10 with affective psychosis (8 with bipolar disorder and 2 with major depression). These 2 subgroups were compared with the 42 control cases from the second set of analyses (Table 3). The number of remaining first-episode patients (4 with schizoaffective disorder and 2 with psychotic disorder not otherwise specified) was too small to form a third subgroup and thus these patients were excluded.

Given the reduced size of the first-episode subgroups, it was decided to maximize power by including covariates found to be statistically significant from the second set of analyses. These covariates were sex (t128 = −2.83, P = .006) and premorbid IQ (t128 = 2.75, P = .007) for whole-brain volume, and whole-brain volume (t128 = 6.41, P < .001) only for hippocampal volume.

All pairwise mean comparisons (Table 3) employed a generalization of the Fisher least significant difference procedure,31 which avoided the necessity of Bonferroni-correcting the assigned .05 α level. To compare the magnitude of mean differences, and to distinguish substantive from statistically significant results, the Cohen d standardized effect sizes44 (plus 95% confidence intervals) were calculated from the pairwise comparisons. An effect size of 0.20 is typically regarded as being small, 0.50 as being moderate, and 0.80 as being large.31 Associations among volume measures and demographic, clinical, and medication variables were assessed using Pearson product-moment correlations (Table 4).

episode schizophrenia/schizoaffective patients had lower premorbid IQs (t65 = 3.90, P < .001) (Table 1).

There were no significant differences between the chronic schizophrenia, first-episode psychotic, and control groups in whole-brain volume, either without the inclusion of covariates in analysis 1 (F2,215 = 2.48, P = .09) or when controlling for age, sex, height, and premorbid IQ in analysis 2 (F1,201 = 1.36, P = .26). There were no significant differences in whole-brain volume between the control group and first-episode subgroups (F2,65 = 0.34, P = .70) (Table 2).

Analysis 1 revealed significant differences in the hippocampal volumes of the chronic, first-episode, and control groups (F2,213 = 21.16, P < .001), but these differences did not vary between the left and right hippocampus (F2,213 = 0.55, P = .58). Subjects in all 3 groups had significantly larger right vs left hippocampal volumes (F2,213 = 84.18, P < .001) (Table 2). As an indication of the differences being observed, 93% of the patients with chronic schizophrenia and 81% of those with first-episode schizophrenia fell below the mean total hippocampal volume of the controls (Figure 1).

To ensure that these differences were not due to differences in hippocampal length (defined as the number of slices traced per hippocampus), subsidiary analyses were carried out on hippocampal length, covarying for whole-brain volume. There were no significant differences in mean right hippocampal length (controls, 22.9 ± 2.0; chronic schizophrenia, 23.2 ± 2.1; first-episode psychosis, 22.3 ± 2.0 [F2,205 = 2.15, P = .12]), nor in mean left
hippocampal length (controls, 23.5 ± 2.1; chronic schizophrenia, 23.8 ± 2.4; first-episode psychosis, 22.8 ± 2.0 [F2,205 = 2.15, P = .12]).

The differences observed in analysis 1 were maintained when age, sex, height, premorbid IQ, and whole-brain volume were included as covariates (analysis 2, Table 3). There were significant group (F1,103 = 5.40, P = .006) and laterality (F1,103 = 39.29, P < .001) effects, but group differences did not vary according to left or right hippocampus (F2,103 = 1.17, P = .31). Planned comparisons indicated that the chronic and first-episode groups significantly differed from controls for both left and right hippocampal volumes. These significant differences corresponded to moderate effects on average, ranging from 0.406 to 0.586 in size, and represent adjusted hippocampal volumes that were smaller for patients with first-episode (right, 5.3% smaller; left, 8.1% smaller) and chronic schizophrenia (right, 8.1% smaller; left, 7.6% smaller). There were no significant differences between the 2 patient groups for either side.

There were significant differences in hippocampal volume among the 2 first-episode subgroups and controls (F2,64 = 3.31, P = .04) when controlling for whole-brain volume (analysis 3, Table 3). Paired comparisons revealed that control subjects had significantly larger left hippocampal volume than first-episode patients with schizophrenia (t64 = 2.48, P = .02) and affective psychosis (t64 = 2.01, P < .05). The 2 first-episode groups did not significantly differ from each other (t64 = 0.79, P = .94). Compared with the control group, adjusted left hippocampal volumes were 8.1% smaller for the schizophrenia/schizophreniform subgroup and 7.7% smaller for the affective psychosis subgroup (Figure 2).

No significant associations were found in either patient group between whole-brain volume measures and age, duration of illness, age at first admission, or medication dosage. A smaller right hippocampus was associated with longer illness duration in patients with chronic schizophrenia. There were no associations between hippocampal volumes and age at first admission or medication dosage. Hippocampal volumes, right and left, were associated with whole-brain volume in the control and first-episode groups, but only left hippocampal volume was associated with whole-brain volume in the patients with chronic schizophrenia. These associations between whole-brain/hippocampal measures and age/illness duration suggest that patients with chronic schizophrenia and longer illness duration have smaller right hippocampal but not smaller brain size (Table 4).

This study has identified smaller hippocampal volumes bilaterally in patients with chronic schizophrenia and first-episode psychosis, in comparison with controls. Analysis of patients with schizophrenia/schizophreniform psychosis and affective psychosis showed significantly smaller left hippocampal volumes than in control subjects. Right hippocampal volume was associated with increasing illness duration in patients with chronic schizophrenia.
These differences in hippocampal volumes were not accounted for by differences in whole-brain volume, age, sex, height, premorbid IQ, or handedness. Whole-brain volumes did not differ for any of the patient groups as compared with controls.

The percentage difference in whole-brain volume found in our patients with chronic schizophrenia, though not significant, compares with previous neuropathological55 and MRI findings.56,57 A recent longitudinal MRI first-episode study57 identified smaller whole-brain volumes of our controls was not seen in the patients over the period of the study. DeLisi et al34 found no differences in brain volume at illness onset but a reduction in hemispheric volume in patients 4 years after illness onset,35,36 suggesting progressive structural changes.

The current study found that age-related reduction in whole-brain volumes of our controls was not seen in the 2 patient groups, though the failure to detect such a reduction may be due to the narrower age range in the patient groups. No longitudinal MRI studies beyond the first episode samples.64 Further, while patients with chronic schizophrenia were well-matched to controls,13 there was no matching for the first-episode patients.42 Also, height and whole-brain volume in patients with first-episode and chronic schizophrenia as compared with controls were limited by the use of qualitative ratings.59,60

Fukuzako et al,13,42 using thin MRI slices, ascribed smaller hippocampal volumes in chronic and first-episode patients to shortening of the hippocampus, but failed to report volumes in the first-episode group.65 Further, while patients with chronic schizophrenia were well-matched to controls,13 there was no matching for the first-episode patients.42 Also, height and whole-brain volume were controlled for in the first-episode study and, to adjust for the sex ratio difference between the groups, they adjusted the female hippocampal length to that of the males.52 In contrast to these findings, our results in chronic schizophrenia and first-episode psychoses suggest that smaller hippocampi could not be accounted for by reduced length.

Smaller hippocampal volumes were not specific to the first-episode patients with schizophrenia/schizophreniform psychosis but were also seen in first-episode affective psychosis. Previous reports in bipolar disorder have described ventricular enlargement,61,62 smaller right hippocampi in men,40 and no hippocampal area change.63 The present findings, suggesting non-specific hippocampal volume reduction, must be regarded as preliminary owing to the small numbers in each subgroup and possible diagnostic instability in first-episode patients assessed at an early stage.64 However, diagnostic stability in our sample, using a comprehensive assessment method,45 is approximately 90% at 2 years (unpublished data, 1997), which is higher than other first-episode samples.64 Further, the failure to identify smaller right hippocampal volumes in the first-episode subgroups may also be owing to the small numbers in each subgroup.

Neuropathological studies in schizophrenia, some of which have detected smaller hippocampi,65-67 support the concept of an early, nonprogressive lesion of the hippocampus.2 The evidence supporting a neurodegenerative model of schizophrenia is scant,68 although there have been recent findings from longitudinal MRI studies of reductions in the volumes of the frontal57 and temporal lobes, but not the hippocampi,56 in first-episode patients. Our finding of an association between smaller right hippocampal volume and increasing illness duration in chronic schizophrenia would support the concept of biological toxicity of illness,69 in which repeated episodes or continuous unremitting symptoms lead to hippocampal shrinkage. This explanation would, however, also predict progressive left hippocampal volume reduction. An alternative explanation is that patients with smaller hippocampi bilaterally are more likely to have a chronic course. Prospective longitudinal
Table 3. Adjusted Whole-Brain and Hippocampal Volume Means (Analyses 2 and 3)*

<table>
<thead>
<tr>
<th>No. of Patients</th>
<th>Adjusted Whole-Brain Volume, mm³</th>
<th>Percent Difference†</th>
<th>Right Hippocampus, mm³</th>
<th>Percent Difference</th>
<th>Left Hippocampus, mm³</th>
<th>Percent Difference</th>
<th>Compared With Chronic Schizophrenia§</th>
<th>Compared With First-Episode Psychosis¶</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analysis 2: Chronic/First-Episode/Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>46</td>
<td>1,326,654 (122,258)</td>
<td>3.3</td>
<td>2,897 (319)</td>
<td>10.1</td>
<td>2,705 (317)</td>
<td>11.4</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>1,328,485 (157,792)</td>
<td>3.2</td>
<td>2,931 (408)</td>
<td>9.0</td>
<td>2,709 (448)</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>First-episode schizophrenia</td>
<td>16</td>
<td>1,341,754 (134,896)</td>
<td>2.2</td>
<td>2,939 (392)</td>
<td>8.8</td>
<td>2,711 (521)</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>10</td>
<td>1,376,679 (166,654)</td>
<td>0.0</td>
<td>3,051 (302)</td>
<td>5.3</td>
<td>2,775 (425)</td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td>First-episode schizophrenia</td>
<td>4</td>
<td>1,322,490 (195,961)</td>
<td>10.2</td>
<td>2,709 (217)</td>
<td>15.9</td>
<td>2,612 (264)</td>
<td>14.4</td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>140</td>
<td>1,372,088 (144,437)</td>
<td>17.4</td>
<td>2,713 (7)</td>
<td>15.8</td>
<td>2,690 (454)</td>
<td>16.1</td>
<td></td>
</tr>
<tr>
<td>Analysis 3: First-Episode Subgroups/Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>16</td>
<td>1,345,159 (126,991)</td>
<td>4.4</td>
<td>2,885 (337)</td>
<td>10.2</td>
<td>2,763 (333)</td>
<td>9.8</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>10</td>
<td>1,341,754 (134,896)</td>
<td>4.6</td>
<td>2,939 (392)</td>
<td>8.5</td>
<td>2,711 (521)</td>
<td>11.5</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>10</td>
<td>1,376,679 (166,654)</td>
<td>2.1</td>
<td>3,051 (302)</td>
<td>5.0</td>
<td>2,775 (425)</td>
<td>9.4</td>
<td></td>
</tr>
<tr>
<td>Right hippocampus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>34</td>
<td>2,903 (±139)</td>
<td>8.0</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>2,986 (±126)</td>
<td>5.4</td>
<td>0.814</td>
<td>0.163</td>
<td>2.031</td>
<td>0.406</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>16</td>
<td>3,157 (±112)</td>
<td>.</td>
<td>2.569</td>
<td>0.514</td>
<td>2.031</td>
<td>0.406</td>
<td></td>
</tr>
<tr>
<td>Left hippocampus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>34</td>
<td>2,779 (±135)</td>
<td>7.6</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>2,765 (±123)</td>
<td>8.0</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>10</td>
<td>3,006 (±109)</td>
<td>.</td>
<td>2.356</td>
<td>0.471</td>
<td>2.931</td>
<td>0.586</td>
<td></td>
</tr>
</tbody>
</table>

*Data are presented as mean (SD) unless otherwise specified.
†Percent smaller compared with normal controls.
§For analysis 3, compared with first-episode schizophrenia.
¶For analysis 3, compared with first-episode affective psychosis.

Table 2. Absolute Whole-Brain and Hippocampal Volumes*

<table>
<thead>
<tr>
<th>No. of Patients</th>
<th>Whole-Brain Volume, mm³</th>
<th>Percent Difference†</th>
<th>Right Hippocampus, mm³</th>
<th>Percent Difference</th>
<th>Left Hippocampus, mm³</th>
<th>Percent Difference</th>
<th>Compared With Chronic Schizophrenia§</th>
<th>Compared With First-Episode Psychosis¶</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analysis 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>46</td>
<td>1,326,634 (122,258)</td>
<td>3.3</td>
<td>2,897 (319)</td>
<td>10.1</td>
<td>2,705 (317)</td>
<td>11.4</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>1,328,485 (157,792)</td>
<td>3.2</td>
<td>2,931 (408)</td>
<td>9.0</td>
<td>2,709 (448)</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>First-episode schizophrenia</td>
<td>16</td>
<td>1,341,754 (134,896)</td>
<td>2.2</td>
<td>2,939 (392)</td>
<td>8.8</td>
<td>2,711 (521)</td>
<td>11.2</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>10</td>
<td>1,376,679 (166,654)</td>
<td>0.0</td>
<td>3,051 (302)</td>
<td>5.3</td>
<td>2,775 (425)</td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td>Right hippocampus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>34</td>
<td>2,903 (±139)</td>
<td>8.0</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>2,986 (±126)</td>
<td>5.4</td>
<td>0.814</td>
<td>0.163</td>
<td>2.031</td>
<td>0.406</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>16</td>
<td>3,157 (±112)</td>
<td>.</td>
<td>2.569</td>
<td>0.514</td>
<td>2.031</td>
<td>0.406</td>
<td></td>
</tr>
<tr>
<td>Left hippocampus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic schizophrenia</td>
<td>34</td>
<td>2,779 (±135)</td>
<td>7.6</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td>32</td>
<td>2,765 (±123)</td>
<td>8.0</td>
<td>0.943</td>
<td>0.183</td>
<td>1.608</td>
<td>0.320</td>
<td></td>
</tr>
<tr>
<td>First-episode affective</td>
<td>10</td>
<td>3,006 (±109)</td>
<td>.</td>
<td>2.356</td>
<td>0.471</td>
<td>2.931</td>
<td>0.586</td>
<td></td>
</tr>
</tbody>
</table>

*Data are presented as mean (SD) unless otherwise specified.
†Percent smaller compared with normal controls.
§For analysis 3, compared with first-episode schizophrenia.
¶For analysis 3, compared with first-episode affective psychosis.

ARCH GEN PSYCHIATRY/VOL 56, FEB 1999

©1999 American Medical Association. All rights reserved.
studies, ideally beginning with prepsychotic individuals, are required to address these possibilities.

While our findings are partially consistent with a neurodevelopmental model, alternative explanations, such as medication and chronic stress, may be relevant. A medication effect is unlikely for 2 reasons. First, medication dosage was not associated with hippocampal volume in any patient group. Second, antipsychotic-mediated hippocampal volume reduction in the first-episode group would need to have occurred, to the same degree as in patients with chronic schizophrenia, within 31 days of treatment. The “cortisol-cascade hypothesis” may be relevant to hippocampal shrinkage given findings from both animal and human literature that chronic stress–induced cortisol secretion may lead to hippocampal degeneration. The finding of smaller left, rather than bilateral, hippocampal volumes would, however, be difficult to explain as an effect of either stress or medication.

There are several methodological limitations of this study. First, diagnosis in a first-episode group may alter following first presentation, emphasizing the importance of a longitudinal approach. Second, the finding of smaller left hippocampi in the first-episode subgroups, but a bilateral difference in the combined first-episode group, may be due to the small numbers in the subgroups. This finding needs to be replicated with larger sample sizes. Third, the finding of an association between illness duration and right hippocampal volume in the chronic schizophrenia group, but not the first-episode group, may be due to a lack of variance in illness duration in the first-episode patients. Fourth, there was no correction for variations of head position during scanning, although this is unlikely to be problematic with...
Our finding of bilaterally smaller hippocampal volume in chronic schizophrenia is consistent with a recent meta-analysis of MRI hippocampal studies in schizophrenia. Further, our results in first-episode patients identified bilaterally smaller hippocampi soon after illness onset, which addresses one of the recommendations for further study made by Nelson et al. While our findings provide support for the neurodevelopmental hypothesis by suggesting that hippocampal abnormalities are present at illness onset, they support neither the prediction that such changes are specific to schizophrenia nor the prediction that the lesion is nonprogressive. The further investigation of these latter 2 predictions requires longitudinal studies beginning with a large cohort of high-risk individuals prior to the onset of psychosis.

Accepted for publication October 2, 1998.

This research was supported by the Schizophrenia Research Unit, the National Health and Medical Research Council, the Australian Communications and Computing Institute, the Jack Brockhoff Foundation, the Ian Potter Foundation, the L. E. W. Cary Trust, and the Percy Baxter Charitable Trust, Melbourne, Australia. Dr Velakoulis is currently supported as a National Health and Medical Research Council Research Officer.

Reprints: Dennis Velakoulis, FRANZCP, Mental Health Research Institute, Locked Bag 11, Parkville 3052, Victoria, Australia.

REFERENCES

5. Sharpio RM. Regional neuropathology in schizophrenia: where are we? where are we going? Schizophr Res. 1993;10:187-239.
34. DeLisi LE, Hoff AL, Schwartz JE, Shields OW, Haltwine SN, Gupta SM, Henn FA, ©1999 American Medical Association. All rights reserved.


